tiprankstipranks
Trending News
More News >

David Shook Insider Profile

4 Followers
David Shook, Chief Medical Officer, Head of Research & Development at Nkarta, holds 21.90K shares in Lyell Immunopharma (Ticker: LYEL), holds 190.96K shares in Nkarta (Ticker: NKTX).
tipranks
David Shook

David Shook
Nkarta (NKTX)
Chief Medical Officer, Head of Research & Development

Ranked #81,452 out of 102,830 Corporate Insiders

Profitable Transactions

60%
3 out of 5 Profitable Transactions

Average Return

-20.90%
Average return per transaction
Time Frame
1 Year
Compare to
No Benchmark

Insider Holdings

$646K
61.23%
38.77%
A breakdown of David Shook's holdings

Insider Roles

Nkarta
(NKTX)
Chief Medical Officer, Head of Research & Development
Lyell Immunopharma
(LYEL)
Chief Medical Officer
Roles that David Shook holds in companies

Most Profitable Insider Trade

Stock:
Nkarta
(NKTX)
Rating:Informative Sell
Date:Jan 18, 2024 - Jan 18, 2025
Return:+70.90%
The most profitable trade made by David Shook

David Shook's Trading History

Company Name
Last Transaction Date
Insider Position
Last Transaction
Last Transaction Amount
Holding Value
Nkarta
Jan 17, 2025
Chief Medical Officer, Head of Research & Development
Informative Sell
19.00K
$395.28K
Lyell Immunopharma
Jun 11, 2025
Chief Medical Officer
Uninformative Buy
$250.32K
List of latest transactions for each holding click on a transaction to see David Shook's performance on stock

David Shook insider profile FAQ

What is the percentage of profitable transactions made by David Shook?
The percentage of profitable transactions made by David Shook is 60%.
    What is the average return per transaction made by David Shook?
    The average return per transaction made by David Shook is -20.90%.
      What stocks does David Shook hold?
      David Shook holds: NKTX, LYEL stocks.
        What was David Shook’s latest transaction?
        David Shook latest transaction was an Uninformative Buy of ―.
          What was David Shook's most profitable transaction?
          David Shook’s most profitable transaction was an Informative Sell of NKTX stock on January 18, 2024. The return on the trade was 70.90%.
            What is David Shook's role in Nkarta?
            David Shook's role in Nkarta is Chief Medical Officer, Head of Research & Development.
              How can I follow the stock ratings of top corporate insiders?
              Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.